NCT00910442

Brief Summary

The aim of this study is to investigate the responses of the serum amyloid A (SAA) pathway to dietary supplements of glutamine (Gln) and cysteine (Cys) together with methionine (Met)-overloading in HIV+ patients comparatively to healthy controls.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Feb 2002

Longer than P75 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2002

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2007

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 27, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 29, 2009

Completed
Last Updated

May 29, 2009

Status Verified

May 1, 2009

Enrollment Period

5 years

First QC Date

May 27, 2009

Last Update Submit

May 28, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • Plasma glutathione

    7 days

Secondary Outcomes (1)

  • Plasma sulfur amino acids

    7 days

Study Arms (2)

Patient Group

EXPERIMENTAL

Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.

Dietary Supplement: Glutathione precursors

Control Group

ACTIVE COMPARATOR

Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.

Dietary Supplement: Glutathione precursors

Interventions

Glutathione precursorsDIETARY_SUPPLEMENT

HIV+ patients were assigned to 7 day diets containing either NAC or Gln

Also known as: Glutamine (L-glutamine), NAC (N-acetyl-L-cysteine)
Control GroupPatient Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • HIV infection
  • antiretroviral therapy for at least one year

You may not qualify if:

  • presence of any renal or liver failure
  • ingestion of either vitamins B or GSH precursors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Burini RC, Borges-Santos MD, Moreto F, Yu YM. Comparative effects of acute-methionine loading on the plasma sulfur-amino acids in NAC-supplemented HIV+ patients and healthy controls. Amino Acids. 2018 May;50(5):569-576. doi: 10.1007/s00726-018-2538-2. Epub 2018 Feb 1.

  • Borges-Santos MD, Moreto F, Pereira PC, Ming-Yu Y, Burini RC. Plasma glutathione of HIV(+) patients responded positively and differently to dietary supplementation with cysteine or glutamine. Nutrition. 2012 Jul;28(7-8):753-6. doi: 10.1016/j.nut.2011.10.014. Epub 2012 Jan 20.

MeSH Terms

Conditions

HIV Infections

Interventions

GlutamineAcetylcysteine

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

Amino Acids, BasicAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, DiaminoAmino Acids, NeutralCysteineAmino Acids, SulfurSulfur CompoundsOrganic Chemicals

Study Officials

  • Roberto C Burini, PhD

    UNESP Medical School

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 27, 2009

First Posted

May 29, 2009

Study Start

February 1, 2002

Primary Completion

February 1, 2007

Study Completion

February 1, 2009

Last Updated

May 29, 2009

Record last verified: 2009-05